Vivo Opportunity Fund Holdings, L.P. - 30 Sep 2025 SCHEDULE 13G/A Report for Soleno Therapeutics, Inc. Common Stock, $0.001 par value per share (SLNO)

Filing Manager
Vivo Opportunity Fund Holdings, L.P.
Reporting Manager
Vivo Opportunity Fund Holdings, L.P.
Security
Soleno Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol
SLNO
Shares outstanding
53,599,048 shares
Disclosed Ownership
2,251,160 shares
Ownership
4.2%
Form type
SCHEDULE 13G/A
Filing time
14 Nov 2025, 18:35:00 UTC
Date of event
30 Sep 2025
Previous filing
12 Aug 2025
SEC
View on sec.gov

Quoteable Key Fact

"Vivo Opportunity Fund Holdings, L.P. disclosed 4.2% ownership in Soleno Therapeutics, Inc. Common Stock, $0.001 par value per share (SLNO) on 30 Sep 2025."

Quick Takeaways

  • Vivo Opportunity Fund Holdings, L.P. filed SCHEDULE 13G/A for Soleno Therapeutics, Inc. Common Stock, $0.001 par value per share (SLNO).
  • Disclosed ownership: 4.2%.
  • Date of event: 30 Sep 2025.

What Changed

  • Previous schedule filing date: 12 Aug 2025.
  • Current filing was accepted on 14 Nov 2025, 18:35.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (4)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Vivo Opportunity Fund Holdings, L.P. 4.2% 2,251,160 2,251,160 0 /s/ Kevin Dai Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Vivo Opportunity, LLC 4.2% 2,251,160 2,251,160 0 /s/ Kevin Dai Kevin Dai/Managing Member
Vivo Opportunity Cayman Fund, L.P. 0.1% 27,043 27,043 0 /s/ Kevin Dai Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner
Vivo Opportunity Cayman, LLC 0.1% 27,043 27,043 0 /s/ Kevin Dai Kevin Dai/Managing Member